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BACKGROUND AND PURPOSE: PV is increasingly used as treatment for osteoporotic VCFs. However,
controversy exists as to whether PV increases the risk for new VCFs during follow-up. The purpose of
our research was to assess the incidence of new VCFs in patients with acute VCFs randomized to PV
and conservative therapy.
MATERIALS AND METHODS: VERTOS II is a prospective multicenter randomized controlled trial com-
paring PV with conservative therapy in 202 patients. Incidence, distribution, and timing of new VCFs
during follow-up were assessed from spine radiographs. In addition, further height loss during follow-
up of treated VCFs was measured.
RESULTS: After a mean follow-up of 11.4 months (median, 12.0; range, 1–24 months), 18 new VCFs
occurred in 15 of 91 patients after PV and 30 new VCFs in 21 of 85 patients after conservative therapy.
This difference was not significant (P  .44). There was no higher fracture risk for adjacent-versus-
distant vertebrae. Mean time to new VCF was 16.2 months after PV and 17.8 months after conser-
vative treatment (logrank, P  .45). The baseline number of VCFs was the only risk factor for
occurrence (OR, 1.43; 95% CI, 1.05–1.95) and number (P  .01) of new VCFs. After conservative
therapy, further height loss of treated vertebrae occurred more frequently (35 of 85 versus 11 of 91
patients, P  .001) and was more severe (P  .001) than after PV.
CONCLUSIONS: Incidence of new VCFs was not different after PV compared with conservative therapy
after a mean of 11.4 months’ follow-up. The only risk factor for new VCFs was the number of VCFs at
baseline. PV contributed to preservation of stature by decreasing both the incidence and severity of
further height loss in treated vertebrae.
ABBREVIATIONS: CI  confidence interval; FREE  Efficacy and Safety of Balloon Kyphoplasty
Compared with Nonsurgical Care for Vertebral Compression Fracture; OR  odds ratio; PV 
percutaneous vertebroplasty; VAS  Visual Analogue Scale; VCF  vertebral compression fracture;
VERTOS  Percutaneous Vertebroplasty Versus Conservative Therapy
V
CFsarethemostcommonfracturesassociatedwithosteo-
porosis.
1 In the elderly population with osteoporosis,
VCFs may lead to morbidity and even mortality due to inca-
pacitating back pain, decreased daily activity, and increased
daysofbedrest.
2,3Inaddition,deteriorationofstature,suchas
severe thoracic kyphosis, may contribute to morbidity by de-
creased pulmonary function or higher risk of falling. Fortu-
nately, only a minority of VCFs cause such severe pain that
patientsseekmedicalattention.
4Whenpainresponsetoanal-
gesics is insufficient during several weeks, PV is increasingly
usedasaminimallyinvasivetechniquetoinducedurablepain
relief. However, some authors believe that PV is associated
with a higher incidence of new VCFs as a result of the aug-
mentedstiffnessofthetreatedvertebra,relatedtotheamount
of injected cement or by cement leakage in the adjacent verte-
bral disk space.
5-8 Others dispute this assumption and con-
sider the incidence of new VCFs dependent on the presence
andseverityofosteoporosis.
9-13Toelucidatethiscontroversy,
we assessed the incidence of new VCFs during follow-up in
202 patients with acute VCFs randomized to PV and conser-
vative therapy from VERTOS II.
14 In addition, we assessed
furtherheightlossofthetreatedvertebraewithboththerapies.
Materials and Methods
Patients
The detailed study design has previously been published.
14 In short,
weperformedarandomizedcontrolledtrialcomparingPVwithcon-
servative therapy in selected patients with acute VCF in 5 large teach-
ing hospitals in the Netherlands and 1 in Belgium. Inclusion criteria
werethefollowing:1)VCFonspineradiograph(minimal15%lossof
height), 2) level of VCF T5 or lower, 3) back pain for 6 weeks, 4)
VAS score of 5 on a 0–10 scale, 5) bone edema of the fractured
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AJNR Am J Neuroradiol 31:1447–50  Sep 2010  www.ajnr.org 1447vertebral body on MR imaging, 6) focal tenderness on the VCF level,
and7)decreasedboneattenuationwitht-scoresequalorlessthan1.
Exclusion criteria were the following: 1) severe cardiopulmonary co-
morbidity, 2) untreatable coagulopathy, 3) infection, 4) suspected
alternative underlying malignancy, 5) radicular syndrome, 6) my-
elum compression syndrome, and 7) contraindication for MR imag-
ing. The study protocol was approved by the institutional review
board at each participating center.
Procedures
Participants were randomly assigned to PV or conservative therapy.
PV was performed under biplane fluoroscopy with bilateral trans-
pedicular injection of bone cement. Native CT of the spine was per-
formed to detect possible cement leakage. Conservative therapy con-
sistedofanalgesicsoptimizedinclassificationanddosebyaninternist
on a daily basis. Patients in both treatment groups received bisphos-
phonates, calcium supplementation, and vitamin D. Symptomatic
newVCFsweretreatedaccordingtotheoriginallyallocatedtreatment
strategy.
Imaging
At baseline, radiography and MR imaging of the spine were per-
formed. Spine radiographs were repeated at 1-, 3-, and 12-month
follow-up. Two radiologists independently performed semiquantita-
tive and quantitative morphometric assessments at baseline and fol-
low-upimaging.
15,16A“newVCF”wasdefinedasadecreaseofatleast
4 mm in vertical dimension.
17 Height loss in new VCFs was catego-
rized as mild, moderate, and severe. Distribution of new VCFs was
classified as adjacent to a treated level, between treated levels, and
distant to a treated level.
18 “Further height loss” during follow-up of
treated baseline VCFs with bone edema was defined as height loss of
4 mm and was categorized as moderate (4–7 mm) and severe (8
mm). Disagreement between observers was resolved in a consensus
meeting. Because bone cement is radiopaque, treatment assignment
could not be blinded.
Statistical Analysis
Patient characteristics were compared. A t-test was used for means,
and a 
2 test for proportions. The incidence and timing of new VCFs
were analyzed by using survival analysis. The cumulative incidence
was calculated by using Kaplan-Meier estimates. Logistic regression
analysiswasusedtoassessapossiblerelationbetweentheincidenceof
newVCFsandthefollowingfactors:age,sex,randomization,baseline
VAS-score,bonemineralattenuation,numberofprevalentfractures,
fracture severity, number of vertebral levels treated, mean amount of
bone cement injected per vertebra, cement leakage into the disk, ce-
ment leakage into the soft tissue around the vertebra, and cement
leakage into the veins. Linear regression analysis was used to deter-
mineriskfactorsforthenumberofnewVCFs.Analysiswasbyinten-
tion to treat.
Statistical analysis was performed with the Statistical Package for
the Social Sciences, Version 15.0.1 (SPSS, Chicago, Illinois). The
VERTOS II study is registered with ClinicalTrials.gov, with the num-
ber NCT00232466.
Results
Of934patientswhowerescreenedbetweenOctober2005and
June2008,202mettheinclusioncriteriaandagreedtopartic-
ipate in the study. Of the 202 participating patients, 101 were
assignedtoPVand101toconservativetherapy.Baselinechar-
acteristics were similar (Table 1). Informed consent was with-
drawn after randomization by 6 patients assigned to conser-
vative therapy and 2 patients assigned to PV. These patients
had no therapy, and follow-up could not be obtained. Six pa-
tients assigned to PV did not receive this treatment because of
poor health (n  3) and spontaneous pain relief (n  3).
Follow-up was obtained in 5 of these 6 patients. Ten patients
assigned to conservative therapy with ongoing invalidating
pain requested and received PV during follow-up. Five of
these 10 patients withdrew informed consent, so the PV pro-
cedure could not be documented and analyzed. Finally, 81%
of the participants completed the follow-up at 1 year.
PV was performed in 98 patients on 134 vertebrae in 103
procedures. The mean volume of injected cement per verte-
bral body was 4.10 mL (range, 1–9 mL). CT of the 134 treated
vertebral bodies showed cement leakage in 97 (72%). Most
leakageswereintoadjacentdisksorsegmentalveins;therewas
Table 1: Baseline characteristics of 202 randomized patients
PV
Conservative
Therapy
P
Value
No. of patients 101 101
Age 75.2  9.8 75.4  8.4 .90
Female sex 70 (69%) 70 (69%) 1.0
Duration of back pain (days) 29.3  17.1 26.8  16.0 .46
Initial VAS 7.8  1.5 7.5  1.6 .12
Mean no. of VCFs at baseline (range) 2.4  1.9 (1–5) 2.1  1.5 (1–5) .24
No./grading of VCFs with bone edema 136 120
Mild 57 55 .59
Moderate 58 45
Severe 21 20
Wedge 90 97 .18
Biconcave 46 23
Crush 0 0
Vertebral level with bone edema
T5-T10 19 32 .16
T11-L2 91 66
L3-L5 29 28
Bone density (t-score) 3.0  1.17 3.0  1.05 .78
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asymptomatic.
New VCFs during Follow-Up
After a mean follow-up of 11.4 months (median, 12.0; range,
1–24 months), 18 new fractures were observed in 15 of 91
patients treated with PV and 30 new vertebral fractures were
apparent in 21 of 85 patients treated with conservative ther-
apy.Thisdifferenceinincidencewasnotsignificant(P.44).
New VCFs occurred at 4.6  5.4 months after PV and 6.1 
5.9 months after conservative therapy (P  .48).
The distribution of new VCFs is shown in Table 3. Distri-
bution of location was not significantly different (P  .23).
There was no higher fracture risk for adjacent-versus-distant
vertebrae.
Time to new VCF is graphically displayed in Fig 1. The
Kaplan-Meier estimate of the mean time to incident was
16.2 months after PV and 17.8 months after conservative
treatment. This difference was not significant (logrank,
P  .45).
The baseline number of vertebral fractures was the only
riskfactorfortheoccurrenceofnewVCFs(OR,1.43;95%CI,
1.05–1.95) and also for the number of new VCFs (P  .01).
Further height loss during follow-up of treated baseline
VCFs with bone edema was observed in 11 vertebrae in 11 of
91 patients after PV and in 39 vertebrae in 35 of 85 patients
after conservative therapy. Further height loss occurred more
frequentlyinpatientsafterconservativetherapy(35of85ver-
sus 11 of 91 patients, P  .001). Severity grading of further
height loss is shown in Table 3. After conservative therapy,
further height loss was significantly more severe than after PV
(P  .001)
Discussion
We found that PV does not increase the risk of new vertebral
fractures in the first year. The incidence and distribution of
new VCFs were similar after PV and conservative therapy.
AfterPV,therewasnohigherfractureriskforadjacent-versus-
distantvertebrae.AfterbothPVandconservativetherapy,the
only risk factor for the occurrence of new VCFs was the num-
berofVCFsatbaseline.ThisnumberofbaselineVCFsinturn
isassociatedwiththeseverityofosteoporosis.Thus,theoccur-
renceofnewVCFsisduetotheongoingosteoporosisonlyand
not to the type of therapy.
Our study shows that PV prevented further height loss of
thetreatedfracturedvertebralbodiesinmostpatients.Appar-
ently,theinjectedcementstrengthenedthefracturedvertebral
body. This is an important advantage in the prevention of
morbidity associated with deterioration of stature such as se-
vere kyphosis with decreased pulmonary function. PV not
only decreased the incidence but also the severity of further
height loss in affected vertebrae, thus further contributing to
preservation of stature.
Our study is the first randomized controlled trial evaluat-
ing the risk of new VCFs in the first year after PV in a large
patientcohort.Theonlylimitationofourstudywastheinabil-
ity to blind treatment assignment due to the radio-opacity of
thebonecementusedinPV.Astudywithacomparabledesign
is the FREE study, which compared kyphoplasty with conser-
vative treatment in 300 patients with acute VCFs.
19 Kypho-
plasty involves an inflatable bone tamp to preform a space for
the bone cement instead of a direct cement injection into the
vertebralbodyasinPV.InthisFREEstudy,anequalincidence
of new VCFs was also found after kyphoplasty and conserva-
tive treatment but risk factors for new VCFs, distribution of
new VCFs, and further height loss of treated VCFs at baseline
were not analyzed.
The findings of our study and the FREE study are in con-
cordance with other studies.
9-13,20 On the other hand, some
studies have reported an increased risk of new VCFs after
PV.
5,6,8,20,21 However, most of these studies were small non-
randomized follow-up only studies, lacking a control group
without intervention.
Some noncontrolled follow-up studies after PV reported
that new VCFs, more often located adjacent to the vertebro-
plastylevel,allegedlycontributedtotheincreaseddimensional
stability of the cemented vertebral body.
6,8,22,23 However, in
our randomized study, no difference in location distribution
of new VCFs was found after PV and conservative therapy. In
addition, after PV, the risk for a new VCF adjacent to the
cemented level was equal to the risk of a new VCF at a distant
level.
Table 2: Distribution of new VCFs
Distribution
PV
(n  91)
Conservative
Therapy
(n  85)
P
Value
Adjacent 7 11 .23
Between 4 3
Distant 7 16
Fig 1. Kaplan-Meier survival curve for the timing of new VCFs after PV and conservative
therapy.
Table 3: Height loss of the treated VCFs between baseline and last
follow-up
Further Height
Loss of Treated
Vertebrae
PV (n  136
vertebrae)
Conservative
Therapy
(n  120
vertebrae)
P
Value
None (0–3 mm) 118 74 .001
Moderate (4–7 mm) 7 28
Severe (8 mm) 4 11
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body was frequently detected with CT. Most leakages were
into adjacent disks or segmental veins; none were into the
spinal canal. All patients remained asymptomatic. Cement
leakage was not associated with the occurrence of new VCFs
during follow-up, in contradiction to some other studies in
which leakage into an adjacent disk was considered a risk fac-
torfornewVCFs.
5,24PostproceduralCTisnotneededinrou-
tinedailypractice;itisonlyneededincaseswithclinicalsymp-
toms or significant volumes of cement leakage.
Conclusions
TheincidenceofnewVCFsinpatientswithanacuteosteopo-
roticVCFwasnotdifferentafterPVcomparedwithconserva-
tive therapy in the first year of follow-up. The only risk factor
for the occurrence of new VCFs was the number of VCFs at
baseline.PVcontributedtopreservationofstaturebydecreas-
ing the incidence and severity of further height loss in treated
vertebrae.
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